Processa Pharmaceuticals
PCSA
10 hedge funds and large institutions have $448K invested in Processa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
35% more capital invested
Capital invested by funds: $331K → $448K (+$117K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6.48% more ownership
Funds ownership: 0.2% → 6.68% (+6.5%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$193K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$117K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.2K |
| 4 |
Citigroup
New York
|
+$38 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$86.9K |
| 2 |
HF
HRT Financial
New York
|
-$56K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$27.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.29K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$52 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
1
Connective Capital Management
Palo Alto,
California
| $179K | +$193K | +70,736 | New |
|
|
SCM
2
Stonepine Capital Management
Bend,
Oregon
| $139K | +$117K | +42,677 | +346% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $62.8K | +$26.2K | +9,585 | +63% |
|
|
VCM
4
Vanguard Capital Management
Malvern,
Pennsylvania
| $32.1K | +$34.8K | +12,729 | New |
|
|
VFT
5
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $27.4K | +$29.6K | +10,857 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $6.39K | -$27.6K | -10,109 | -80% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $2.32K | -$1.29K | -472 | -34% |
|
|
8
Citigroup
New York
| $35 | +$38 | +14 | New |
|
9
Jones Financial Companies
Des Peres,
Missouri
| $17 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $15 | – | – | – |
|
|
11
Jane Street
New York
| – | -$86.9K | -30,190 | Closed |
|
|
HF
12
HRT Financial
New York
| – | -$56K | -19,691 | Closed |
|
|
13
Bank of America
Charlotte,
North Carolina
| – | -$52 | -18 | Closed |
|
PCSA Hedge Fund Activity: Q1 2026 in Review
10 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2026, worth a combined $448K — up 35% from $331K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PCSA positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Connective Capital Management, opening a new position worth an estimated $193K. The largest seller was Jane Street, exiting entirely with an estimated $86.9K sold.
- 10 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $448K of Processa Pharmaceuticals stock for Q1 2026, up 35% quarter-over-quarter.
- 4 funds opened new Processa Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +1 holder.
- The largest Processa Pharmaceuticals buyer in Q1 2026 was Connective Capital Management, an estimated $193K added.
- The largest Processa Pharmaceuticals seller in Q1 2026 was Jane Street, an estimated $86.9K sold.
Based on aggregated 13F filings for Q1 2026.